Holdings
Paradigm Biocapital Advisors LP
As of Sep 30, 2026, Paradigm Biocapital Advisors LP reported 29 positions worth US$5.01B. Largest: Revolution Medicines, Inc., Genmab A/S and Edgewise Therapeutics, Inc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Revolution Medicines, Inc. | 6.22M | US$1.28B | −142K | Sep 30, 2026 |
| Genmab A/S | 14.1M | US$504M | +1M | Sep 30, 2026 |
| Edgewise Therapeutics, Inc. | 10.8M | US$438M | +563K | Sep 30, 2026 |
| Spyre Therapeutics, Inc. | 4.46M | US$397M | +617K | Sep 30, 2026 |
| Insmed Incorporated | 2.7M | US$308M | +1.37M | Sep 30, 2026 |
| MBX Biosciences, Inc. | 3.77M | US$221M | +1.26M | Sep 30, 2026 |
| Oruka Therapeutics, Inc. | 2.49M | US$208M | +349K | Sep 30, 2026 |
| Belite Bio, Inc. | 1.14M | US$194M | new | Sep 30, 2026 |
| Tarsus Pharmaceuticals, Inc. | 2.3M | US$181M | −474K | Sep 30, 2026 |
| Tango Therapeutics, Inc. | 6.96M | US$174M | +604K | Sep 30, 2026 |